About Shantha Biotech
Shantha Biotech is a Healthcare company based in Hyderabad (India) founded in 1993, and was acquired by Sanofi in July 2009. It operates as a vaccines are developed, manufactured, and marketed for various diseases. The company has 1,076 employees. Its Indian entity Sanofi Healthcare India Private Limited reported revenue of ₹1,726 Cr. Shantha Biotech offers products and services including XTL Plus. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its competitors include Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Shantha Biotech develops, manufactures and markets several vaccines. As of Feb 2016, the company has four vaccines on the market for Hepatitis B, Tetanus, DDT, and Cholera. In addition, Shantha is developing vaccines for rotavirus, HPV, and Typhoid. The Hepatitis B is prequalified by WHO and is distributed to international aid organizations, including UNICEF. In July 2009, Sanofi acquired Shantha Biotech for 784M.
- Headquarters Hyderabad, India
- Employees 1,076
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website shanthabiotech.com
- Acquired by Sanofi (Jul 2009)
- Legal Name Shantha Biotechnics Private Limited
- Date of Incorporation 10 Mar, 1993
- Jurisdiction Mumbai, Maharashtra, India
Associated legal entities of Shantha Biotech
Shantha Biotech operates through Sanofi Healthcare India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sanofi Healthcare India Private Limited CIN U24110MH1993PTC332584 | Active | 10 Mar 1993 | Mumbai, Maharashtra | ₹1,726 Cr | 1,076 | 4 | View details |
Products & Services of Shantha Biotech
Shantha Biotech offers a comprehensive portfolio of products and services, including XTL Plus.
Natural herbal product for male enhancement and sexual health.
Funding Insights of Shantha Biotech
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Shantha Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2007 | – | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Shantha Biotech
Shantha Biotech has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Sanofi and Department of Biotechnology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotechnology research, guidelines, and funding by the Government of India. | 1986 | dbtindia.gov.in | Delhi, India | |
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France |
Investor details for Shantha Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Sanofi Healthcare India Private Limited (Shantha Biotech)
Sanofi Healthcare India Private Limited is the primary company behind Shantha Biotech. The board of Sanofi Healthcare India Private Limited currently have 3 directors; the longest-serving is Saravanan Devarajan, appointed in 2022. 35 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Saravanan Devarajan DIN 09557725 | Whole-time director | 01 Apr 2022 | 4 yrs 6 mo | Sanofi Healthcare India Private Limited |
| Somak Ghosh DIN 10802672 | Additional Director | 13 Nov 2024 | 1 yr 11 mo | Sanofi Healthcare India Private Limited |
| Mayur Dinesh Shah DIN 10812242 | Additional Director | 13 Nov 2024 | 1 yr 11 mo | Sanofi Healthcare India Private Limited |
Financials of Shantha Biotech
Figures of Sanofi Healthcare India Private Limited, the primary company behind Shantha Biotech, for FY 2025. Revenue was ₹1,726 Cr (-18% year on year). Net profit was ₹1,662 Cr (96% margin). EBITDA was ₹2,054 Cr (119% margin). Revenue has grown at a compounded annual rate of -3% over three years and -1% over five years.
- ₹1,726 CrRevenue · FY 2025 · -18% YoY
- ₹1,662 CrNet profit · 96% margin
- ₹2,054 CrEBITDA · 119% margin
- ₹44.14 CrPaid-up capital
- 1,076Employees (provident fund records)
- -3%Revenue CAGR, 3 years
- -1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Sanofi Healthcare India Private Limited are on its company page.
Detailed financial statements for Shantha Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Shantha Biotech
3 dated milestones of Shantha Biotech across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Shantha Biotech is founded.
- Funding First funding round.
- Exit Acquired by Sanofi.
Competitors of Shantha Biotech
Shantha Biotech has 10 listed competitors in our database, 8 of them funded. They include Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. | |
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| valneva.com | 1999 | Lyon, France | $113.55M | – | Prophylactic vaccines for infectious diseases are developed and advanced. | |
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| redhillbio.com | 2009 | Ramat Gan, Israel | $13.5M | 183 | Developer of therapeutics for the treatment of gastrointestinal and infectious diseases |
Detailed competitors of Shantha Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Shantha Biotech
Websites that share an audience with Shantha Biotech (shanthabiotech.com).
Websites whose visitors overlap most with Shantha Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| virchowbiotech.com | 100% | 1.4K | #4,149,585 | View details | |
| vasudhapharma.com | 100% | 6.7K | #1,818,910 | View details | |
| vical.com | 99% | – | – | View details | |
xtralarge.in | xtralarge.in | 87% | – | #14,595,965 | – |
| restat.com | 61% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Shantha Biotech
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Shantha Biotech (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Shantha Biotech
Complete news archive for Shantha Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shantha Biotech
Shantha Biotech was founded in 1993 and raised its 1st funding round 14 years after it was founded.
Shantha Biotech is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Shantha Biotech has 1,076 employees.
The primary company behind Shantha Biotech, Sanofi Healthcare India Private Limited, reported revenue of ₹1,726 Cr for FY 2025, down 18% year on year.
Shantha Biotech develops, manufactures and markets several vaccines. As of Feb 2016, the company has four vaccines on the market for Hepatitis B, Tetanus, DDT, and Cholera. In addition, Shantha is developing vaccines for rotavirus, HPV, and Typhoid. The Hepatitis B is prequalified by WHO and is distributed to international aid organizations, including UNICEF. In July 2009, Sanofi acquired Shantha Biotech for 784M.
Shantha Biotech's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Shantha Biotech offers XTL Plus.
Shantha Biotech has 2 investors. Key investors include Sanofi, and Department of Biotechnology.
Shantha Biotech operates through Sanofi Healthcare India Private Limited.
Yes. Shantha Biotech was acquired by Sanofi in July 2009.
The legal entities of Shantha Biotech currently have 4 directors, including Saravanan Devarajan, Somak Ghosh, Mayur Dinesh Shah and others.